Results 11 to 20 of about 3,791 (213)

Potentially fatal crisis after 177Lu-DOTATATE therapy for paraganglioma: a case report with review of literature [PDF]

Endocrine Journal
Pheochromocytoma/paraganglioma (PPGL) is a rare neuroendocrine tumor with metastatic potential. Peptide receptor radionuclide therapy with 177Lu-DOTATATE, a radiolabeled somatostatin analog, has been used for the treatment of somatostatin receptor ...
Aoki Tobimatsu, Kosuke Mukai, Yoshinari Obata, Kayako Isohashi, Kazuyuki Miyashita, Atsunori Fukuhara, Hiroki Kato, Iichiro Shimomura   +7 more
doaj   +3 more sources

Radiation exposure to families of patients following administration of 177Lu-DOTATATE for the treatment of metastatic neuroendocrine tumours [PDF]

EJNMMI Physics
Background The administration of 177Lu-DOTATATE peptide receptor radionuclide therapy to patients for the treatment of well-differentiated, metastatic neuroendocrine tumours poses an external radiation hazard due to gamma emissions of lutetium-177 ...
D. Levart, S. Wicks, N. Heraghty, E. Kalogianni, N. Mulholland   +4 more
doaj   +3 more sources

Neo-adjuvant systemic radiation therapy for inoperable hepatic hilum neuroendocrine tumor with 177Lu- DOTATATE: successful final surgical resection [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology
The role of neoadjuvant therapy in neuroendocrine tumors (NET) remains an area requiring further advanced clinical exploration. 177Lu-DOTATATE has demonstrated significant therapeutic efficacy in managing metastatic NET, with reports of notable tumor ...
Ali Moradi, Fatemeh Sharifian, Saeed Farzanefar, Mohammad Ghasri, Mehrshad Abbasi   +4 more
doaj   +2 more sources

177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers. [PDF]

Clin Nucl Med, 2023
Purpose Pretreatment predictions of absorbed doses can be especially valuable for patient selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal was to build regression models using pretherapy 68Ga-DOTATATE PET uptake data and other baseline clinical factors/biomarkers to predict renal ...
Peterson AB, Wang C, Wong KK, Frey KA, Muzik O, Schipper MJ, Dewaraja YK.   +6 more
europepmc   +3 more sources

Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE [PDF]

Endocrine Oncology
Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity.
Eleonora Pelle, Taymeyah Al-Toubah, Ghassan El-Haddad, Brian Morse, Bhavana Konda, Vineeth Sukrithan, Jonathan Strosberg   +6 more
doaj   +2 more sources

CTNI-80. 177LU-DOTATATE IN PATIENTS WITH RECURRENT MENINGIOMA [PDF]

Neuro Oncol
Abstract BACKGROUND There are no effective medical therapies for patients with meningioma who progress after surgical and radiotherapeutic interventions. Somatostatin receptor type 2 (SSTR2) represents a promising treatment target in meningiomas.
Nasrollahi, Elham, Drappatz, Jan
europepmc   +3 more sources

Efficacy and safety of 177Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis

Frontiers in Oncology, 2022
ObjectiveTo perform a meta-analysis of the efficacy and safety about 177Lu-DOTATATE therapy for advanced/metastatic pNETs based on the current clinical evidence.MethodsThis systematic review follows the PRISMA guideline.
Lanying Li, Zijuan Rao, Chunyin Zhang
exaly   +3 more sources

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Endocrine Connections, 2020
Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL).
Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar   +12 more
doaj   +3 more sources

The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival [PDF]

ESMO Gastrointestinal Oncology
Background: The aim of this study was to audit clinical and patient-reported outcomes of patients treated with [177Lu]-DOTA-octreotate (177Lu-DOTATATE) at a single Australian centre over an 11-year period.
L.M. Altus, J.C. Forster, J. Mercurio, M. Kitchener, N. Corsini, M. Nenke, T. Price, D. Patel, R. Chew, D. Moffat, S. Unger, G. Cehic   +11 more
doaj   +2 more sources

MRI and 18F-fluorothymidine PET-MR for the early evaluation of renal and bone marrow effects in 177Lu-DOTATATE therapy [PDF]

Endocrine Oncology
Background: This study aimed to evaluate whether early renal and bone marrow effects – previously identified through laboratory tests – can be detected using MRI and 18F-FLT PET-MR in neuroendocrine tumor patients treated with 177Lu-DOTATATE.
Angeliki Dimopoulou Creusen, Edvin Johansson, Per Hagmar, Håkan Ahlström, Dan Granberg   +4 more
doaj   +2 more sources